Basistherapie der Multiplen Sklerose unter „anderen Umständen”: Sicherheit für Patientinnen und ihren Nachwuchs vor, während und nach der Schwangerschaft

Zusammenfassung

Zugelassene Standardbasistherapeutika für Multiple Sklerose (MS) sollen entweder vor oder spätestens mit Eintritt der Schwangerschaft abgesetzt werden [1] [2] [3]. Adäquate Informationen über den Einfluss dieser Präparate auf Gestation, Schwangerschaft und Fetus bzw. auf das Neugeborene und die Stillzeit liegen nicht oder allenfalls nur limitiert vor [1]. Ziel dieser Darstellung ist es, anhand einer Kasuistik das Management der immunmodulatorischen Therapie bei MS-Patientinnen vom Schwangerschaftswunsch bis zur Stillzeit zu verdeutlichen.

Abstract

Standard basic therapeutic agents that are approved for the treatment of multiple sclerosis (MS) should be discontinued before pregnancy or when pregnancy occurs at the latest [1] [2] [3]. There is no adequate or only limited data on the effect of these agents on gestation, pregnancy and the fetus or newborn child as well as lactation [1]. The objective of this presentation is to illustrate on the basis of a case report the management of immunomodulatory therapy in female patients with MS from their wish to become pregnant until lactation.

Schlüsselwörter

Multiple Sklerose - Interferon β - Kinderwunsch - Schwangerschaft

Keywords

multiple sclerosis - interferon β - wish to have a child - pregnancy

Literatur

• 1 Hoffmann L A, Kümpfel T, Heer I. et al . „Andere Umstände”: Schwangerschaft und immunmodulatorische Therapie bei Multipler Sklerose.  Nervenarzt. 2006;  77 663-670
• 2 Rote Liste 2009. ISBN-13: 978-3-939192-30-5. 
• 3 Rote Service GmbH .Fachinfo Service Postfach 11 01 71, 10831. Berlin; Avonex® (Biogen Idec), Rebif® (Merck Serono) Betaferon® (Bayer Schering Pharma), Copaxone® (Teva / Sanofi-Aventis)
• 4 McDonald W I, Compston A, Edan G. et al . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50 121-127
• 5 Kurtzke J F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).  Neurology. 1983;  33 1444-1452
• 6 Michels K B, Xue F, Colditz G A. et al . Induced and spontaneous abortion and incidence of breast cancer among young women.  Arch Intern Med. 2007;  167 814-820
• 7 Sandberg-Wollheim M, Frank D, Goodwin T M. et al . Pregnancy outcomes during treatment with interferon β1a in patients with multiple sclerosis.  Neurology. 2005;  65 802-806
• 8 Boskovic R, Wide R, Wolpin J. et al . The reproductive effects of β interferon therapy in pregnancy.  Neurology. 2005;  65 807-811
• 9 Confavreaux C, Hutchinson M, Hours M M. et al . Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group.  N Engl J Med. 1998;  339 285-291
• 10 Achiron A, Kishner I, Dolev M. et al . Effect of intravenous immunoglobulin treatment on pregnancy and postpartum related relapses in multiple sclerosis.  J Neurol. 2004;  251 1133-1137
• 11 Patti F, Cavallaro T, Lo Fermo S. Is in utero early-exposure to interferon β a risk factor for pregnancy outcomes in multiple sclerosis?.  J Neurol. 2008;  255 1250-1253
• 12 Ferrero S, Esposito F, Pretta S. et al . Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.  Expert Rev Neurotherapeutics. 2006;  6 823-1831
• 13 Houtchens M K. Pregnancy and multiple sclerosis.  Seminars in Neurology. 2007;  27 434-441
• 14 Achiron A, Gabbay U, Gilad R. et al . Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.  Neurology. 1998;  50 398-402
• 15 Fazekas F, Deisenhammer F, Strasser-Fuchs S. et al . Randomised placebo-controlled trial of monthly intravenous immunglobulin therapy in relapsing-remitting multiple sclerosis.  Lancet. 1997;  349 589-593
• 16 Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS.  Mult Scler. 2000;  2 (Suppl. 6) 18-20
• 17 Haas J, Hommes O R. A dose-comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis.  Mult Scler. 2007;  13 900-908
• 18 Orvieto R, Achiron R, Rotstein Z. et al . Pregnancy and multiple sclerosis: a 2-year experience.  Eur J Obstet Gynecol Reprod Biol. 1999;  82 191-194
• 19 Wiendl H, Toyka K V, Rieckmann P. Multiple Sclerosis Therapy Consensus Group (MSTCG) . Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.  J Neurol. 2008;  255 1449-1463
• 20 Winkelmann A, Benecke R, Zettl U K. Effect of intravenous immunoglobulin treatment on pregnancy- and postpartum-related relapses in multiple sclerosis. 6th International Immunoglobulin Symposium 2009. Abstract 46. Interlaken, Schweiz;
• 21 Vukusic S, Hutchinson M, Hours M. et al . Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse.  Brain. 2004;  127 1353-1360